RESIDUAL PROSTATE CANCER IN PATIENTS TREATED WITH ENDOCRINE THERAPY WITH OR WITHOUT RADICAL RADIOTHERAPY: A SIDE STUDY OF THE SPCG-7 RANDOMIZED TRIAL

被引:17
|
作者
Solberg, Arne [1 ]
Haugen, Olav A. [2 ,4 ]
Viset, Trond [2 ]
Bergh, Anders [7 ]
Tasdemir, Ilker [6 ]
Ahlgren, Goran
Widmark, Anders [8 ]
Angelsen, Anders [3 ,5 ]
机构
[1] Univ Trondheim Hosp, Dept Radiotherapy & Oncol, St Olavs Hosp, N-7006 Trondheim, Norway
[2] Univ Trondheim Hosp, Dept Pathol & Med Genet, St Olavs Hosp, N-7006 Trondheim, Norway
[3] Univ Trondheim Hosp, Dept Urol, St Olavs Hosp, N-7006 Trondheim, Norway
[4] Norwegian Univ Sci & Technol, Dept Lab Med, N-7034 Trondheim, Norway
[5] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway
[6] Stavanger Univ Hosp, Dept Urol, Stavanger, Norway
[7] Umea Univ Hosp, Dept Med Biosci Pathol, S-90185 Umea, Sweden
[8] Umea Univ Hosp, Dept Radiat Sci, S-90185 Umea, Sweden
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 80卷 / 01期
关键词
Prostate cancer; Radiotherapy; Endocrine therapy; Posttreatment biopsy; Outcome; CONFORMAL RADIATION-THERAPY; EXTERNAL-BEAM RADIOTHERAPY; PHASE-III TRIAL; DOSE-RESPONSE; ANDROGEN SUPPRESSION; CONSENSUS CONFERENCE; HORMONAL-THERAPY; FOLLOW-UP; BIOPSY; ADENOCARCINOMA;
D O I
10.1016/j.ijrobp.2010.01.072
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The Scandinavian Prostate Cancer Group-7 randomized trial demonstrated a survival benefit of combined,mdocrine therapy and external-beam radiotherapy over endocrine therapy alone in patients with highrisk prostale cancer. In a subset of the study population, the incidence and clinical implications of residual prostate cancer in posttreatment prostate biopsy specimens was evaluated. Methods and Materials: Biopsy specimens were obtained from 120 of 875 men in the Scandinavian Prostate Cancer Group-7 study. Result;: Biopsies were performed at median of 45 months follow-up. In 63 patients receiving endocrine treatment only and 57 patients receiving combined treatment, residual cancer was found in 66% (n = 41) and 22% (n = 12), respectively (p < 0.0001). The vast majority of residual tumors were poorly differentiated (Gleason score >= 8). Endocrine therapy alone was predictive of residual prostate cancer: odds ratio 7.49 (3.18-17.7),p < 0.0001. In patients with positive vs. negative biopsy the incidences of clinical events were as follows: biochemical recurrence 74% vs. 27% (p < 0.0001), local progression 26% vs. 4.7% (p = 0.002), distant recurrence 17% vs. 9.4% (p = 0.27), clinical recurrence 36% vs. 13% (p = 0.006), cancer-specific death 19% vs. 9.7% (p = 0.025). In multivariable analysis, biochemical recurrence was significantly associated with residual cancer: hazard ratio 2.69 (1.45-4.99),p = 0.002, and endocrine therapy alone hazard ratio 3.45 (1.80-6.62), p < 0.0001. Conclusions: Radiotherapy combined with hormones improved local tumor control in comparison with endocrine therapy alone. Residual prostate cancer was significantly associated with serum prostate-specific antigen recurrence, local tumor progression, clinical recurrence, and cancer-specific death in univariable analysis. Residual cancer was predictive of prostate-specific antigen recurrence in multivariable analysis. (C) 2011 Elsevier Inc.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [1] Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
    Widmark, Anders
    Klepp, Olbjorn
    Solberg, Arne
    Damber, Jan-Erik
    Angelsen, Anders
    Fransson, Per
    Lund, Jo-Asmund
    Tasdemir, Ilker
    Hoyer, Morten
    Wiklund, Fredrik
    Fossa, Sophie D.
    LANCET, 2009, 373 (9660) : 301 - 308
  • [2] Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial
    Solberg, Arne
    Widmark, Anders
    Tasdemir, Ilker
    Ahlgren, Goran
    Angelsen, Anders
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2011, 45 (04): : 233 - 238
  • [3] Re: Endocrine Treatment, with or without Radiotherapy, in Locally Advanced Prostate Cancer (SPCG-7/SFUO-3): An Open Randomised Phase III Trial
    Verhagen, Paul C. M. S.
    EUROPEAN UROLOGY, 2009, 55 (05) : 1239 - 1240
  • [4] Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial
    Fransson, Per
    Lund, Jo-Asmund
    Damber, Jan-Erik
    Klepp, Olbjorn
    Wiklund, Fredrik
    Fossa, Sophie
    Widmark, Anders
    LANCET ONCOLOGY, 2009, 10 (04) : 370 - 380
  • [5] Characteristics of Patients in SPCG-15-A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
    Gongora, Magdalena
    Stranne, Johan
    Johansson, Eva
    Bottai, Matteo
    Karlsson, Camilla Thellenberg
    Brasso, Klaus
    Hansen, Steinbjorn
    Jakobsen, Henrik
    Jaderling, Fredrik
    Lindberg, Henriette
    Lilleby, Wolfgang
    Petersen, Peter Meidahl
    Mirtti, Tuomas
    Olsson, Mats
    Rannikko, Antti
    Roder, Martin Andreas
    Vincent, Per Henrik
    Akre, Olof
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 41 : 63 - 73
  • [6] Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy
    Pantarotto, Jason
    Malone, Shawn
    Dahrouge, Simone
    Gallant, Victor
    Eapen, Libni
    BJU INTERNATIONAL, 2007, 99 (03) : 564 - 569
  • [7] Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer
    Furuya, Y
    Akakura, K
    Tanaka, M
    Ichikawa, T
    Igarashi, T
    Murakami, S
    Ito, H
    INTERNATIONAL JOURNAL OF UROLOGY, 2001, 8 (05) : 222 - 226
  • [8] Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy
    Stock, Richard G.
    Cesaretti, Jamie A.
    Hall, Simon J.
    Stone, Nelson N.
    BJU INTERNATIONAL, 2009, 104 (11) : 1631 - 1636
  • [9] SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
    Stranne, J.
    Brasso, K.
    Brennhovd, B.
    Johansson, E.
    Jaderling, F.
    Kouri, M.
    Lilleby, W.
    Petersen, P. Meidahl
    Mirtti, T.
    Pettersson, A.
    Rannikko, A.
    Thellenberg, C.
    Akre, O.
    SCANDINAVIAN JOURNAL OF UROLOGY, 2018, 52 (5-6) : 313 - 320
  • [10] Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
    Lehtonen, Miikka
    Sormunen, Jorma
    Hjalm-Eriksson, Marie
    Thellenberg-Karlsson, Camilla
    Huttunen, Teppo
    Ginman, Claes
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2022, 42 (01) : 87 - 92